ATE343793T1 - Methode zur diagnostizierung, prognose oder evaluation von behandlung der depressionen, basiert auf erhöhte neurotrophin concentrationen in zerebrospinale flüssigkeit. - Google Patents
Methode zur diagnostizierung, prognose oder evaluation von behandlung der depressionen, basiert auf erhöhte neurotrophin concentrationen in zerebrospinale flüssigkeit.Info
- Publication number
- ATE343793T1 ATE343793T1 AT00929470T AT00929470T ATE343793T1 AT E343793 T1 ATE343793 T1 AT E343793T1 AT 00929470 T AT00929470 T AT 00929470T AT 00929470 T AT00929470 T AT 00929470T AT E343793 T1 ATE343793 T1 AT E343793T1
- Authority
- AT
- Austria
- Prior art keywords
- depression
- subject
- prognosis
- diagnosis
- evaluation
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99108723A EP1050758A1 (de) | 1999-05-03 | 1999-05-03 | Methoden zur Diagnostizierung oder zur Behandlung von neuropsychiatrischen Erkrankungen, die auf erhöhten Neurotrophin 3-Spiegel basiert sind |
EP99120212 | 1999-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE343793T1 true ATE343793T1 (de) | 2006-11-15 |
Family
ID=26152989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00929470T ATE343793T1 (de) | 1999-05-03 | 2000-05-02 | Methode zur diagnostizierung, prognose oder evaluation von behandlung der depressionen, basiert auf erhöhte neurotrophin concentrationen in zerebrospinale flüssigkeit. |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080188435A1 (de) |
EP (1) | EP1173768B1 (de) |
AT (1) | ATE343793T1 (de) |
AU (1) | AU4753800A (de) |
DE (1) | DE60031518T2 (de) |
WO (1) | WO2000067032A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3497447A4 (de) * | 2016-07-08 | 2020-01-22 | Biomerica Inc. | Zusammensetzungen, vorrichtungen und verfahren zum testen der depressionsempfindlichkeit |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL95511A (en) * | 1989-08-30 | 2000-10-31 | Max Planck Gesellschaft | Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor |
WO1993009798A1 (en) * | 1991-11-12 | 1993-05-27 | Regeneron Pharmaceuticals, Inc. | Therapeutic and diagnostic methods based on tissue specific nt-3 expression and receptor binding |
DE69327113D1 (de) * | 1992-09-14 | 1999-12-30 | Regeneron Pharma | Methode zum erzeugen von analgie mittels neurotrophine |
IL109280A0 (en) * | 1993-04-15 | 1994-07-31 | Regeneron Pharma | Neurotrophins for treatment of depression |
-
2000
- 2000-05-02 AU AU47538/00A patent/AU4753800A/en not_active Abandoned
- 2000-05-02 WO PCT/EP2000/003912 patent/WO2000067032A1/en active IP Right Grant
- 2000-05-02 DE DE60031518T patent/DE60031518T2/de not_active Expired - Fee Related
- 2000-05-02 AT AT00929470T patent/ATE343793T1/de not_active IP Right Cessation
- 2000-05-02 EP EP00929470A patent/EP1173768B1/de not_active Expired - Lifetime
-
2008
- 2008-01-02 US US12/003,851 patent/US20080188435A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1173768B1 (de) | 2006-10-25 |
US20080188435A1 (en) | 2008-08-07 |
WO2000067032A1 (en) | 2000-11-09 |
EP1173768A1 (de) | 2002-01-23 |
DE60031518T2 (de) | 2007-08-30 |
DE60031518D1 (de) | 2006-12-07 |
AU4753800A (en) | 2000-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE283487T1 (de) | Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration | |
DE60233485D1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
Kahn et al. | Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults | |
MacKenzie et al. | The prevalence of thrombophilia in patients with chronic venous leg ulceration | |
DE60325617D1 (de) | Verfahren zur diagnose von bauchspeicheldrüsenkrebs | |
DE60331941D1 (de) | Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert | |
Temple et al. | Alzheimer dementia in Down's syndrome: the relevance of cognitive ability | |
ATE546734T1 (de) | Risikomarker für eine herzkreislaufkrankheit | |
ATE502119T1 (de) | Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna | |
ATE423217T1 (de) | Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten | |
RU2008103988A (ru) | Способ диагностики рассеяного склероза | |
ATE514948T1 (de) | In vitro verfahren zur diagnose von neurodegenerativen erkrankungen | |
WO2000018954A3 (en) | Use of pex in the treatment of metabolic bone diseases | |
ATE354097T1 (de) | Verfahren zur diagnose von leberfibrose. | |
ATE467834T1 (de) | Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen | |
ATE286253T1 (de) | Methoden zur diagnose oder prognose der alzheimerschen krankheit | |
DE69204157T2 (de) | Verfahren zur bestimmung von anti-rns-antikörpern. | |
ATE343793T1 (de) | Methode zur diagnostizierung, prognose oder evaluation von behandlung der depressionen, basiert auf erhöhte neurotrophin concentrationen in zerebrospinale flüssigkeit. | |
ATE494556T1 (de) | Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1 | |
DE60033646D1 (de) | Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit | |
ATE225405T1 (de) | Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit | |
DE502004012230D1 (de) | Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i | |
ATE449964T1 (de) | DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN | |
ATE392622T1 (de) | Verfahren zur diagnose von leberfibrose | |
RU2696446C1 (ru) | Способ прогнозирования риска развития ожирения в детском возрасте |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |